Shanghai Allist Pharmaceuticals (688578) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was RMB 18.16亿元, up 33.58% YoY; net profit attributable to shareholders was RMB 7.92亿元, up 40.38% YoY.

• 9M revenue reached RMB 51.35亿元, up 37.57% YoY, and attributable net profit was RMB 23.33亿元, up 44.41% YoY, driven by stronger product sales.

Financial highlights

• 9M total profit was RMB 2,725,487,528.19, up 44.30% YoY; Q3 total profit was RMB 924,607,762.39, up 41.54%.

• Adjusted for non-recurring items, attributable net profit was RMB 767,728,492.29 in Q3, up 40.50%, and RMB 2,134,383,895.53 for 9M, up 47.04%.

• 9M operating cash flow was RMB 2,426,236,719, up 40.22% YoY; basic and diluted EPS were RMB 5.19, up 44.41%.

Outlook and guidance

• Commercialization plans call for strengthening platform capabilities and using specialized, differentiated academic promotion to expand the reach of marketed products.

• If approved, furmonertinib’s accepted adjuvant-treatment application would extend its use from advanced disease into post-surgical treatment of early-stage NSCLC.